GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Olympus Corp (OTCPK:OCPNF) » Definitions » Cyclically Adjusted Price-to-FCF

OCPNF (Olympus) Cyclically Adjusted Price-to-FCF : 49.67 (As of Jun. 03, 2025)


View and export this data going back to . Start your Free Trial

What is Olympus Cyclically Adjusted Price-to-FCF?

As of today (2025-06-03), Olympus's current share price is $12.915. Olympus's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was $0.26. Olympus's Cyclically Adjusted Price-to-FCF for today is 49.67.

The historical rank and industry rank for Olympus's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

OCPNF' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 45.08   Med: 72.77   Max: 113.35
Current: 46.58

During the past years, Olympus's highest Cyclically Adjusted Price-to-FCF was 113.35. The lowest was 45.08. And the median was 72.77.

OCPNF's Cyclically Adjusted Price-to-FCF is ranked worse than
61.54% of 247 companies
in the Medical Devices & Instruments industry
Industry Median: 36.39 vs OCPNF: 46.58

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Olympus's adjusted free cash flow per share data for the three months ended in Dec. 2024 was $0.106. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.26 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Olympus Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Olympus's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Olympus Cyclically Adjusted Price-to-FCF Chart

Olympus Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71.31 56.74 58.58 66.24 -

Olympus Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.24 76.66 70.73 59.53 -

Competitive Comparison of Olympus's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Olympus's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Olympus's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Olympus's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Olympus's Cyclically Adjusted Price-to-FCF falls into.


;
;

Olympus Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Olympus's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=12.915/0.26
=49.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Olympus's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Olympus's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.106/110.7000*110.7000
=0.106

Current CPI (Dec. 2024) = 110.7000.

Olympus Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 0.000 97.900 0.000
201506 0.000 98.400 0.000
201509 0.000 98.500 0.000
201512 0.000 98.100 0.000
201603 0.000 97.900 0.000
201606 0.080 98.100 0.090
201609 0.016 98.000 0.018
201612 0.085 98.400 0.096
201703 0.094 98.100 0.106
201706 0.025 98.500 0.028
201709 0.061 98.800 0.068
201712 0.010 99.400 0.011
201803 0.118 99.200 0.132
201806 0.066 99.200 0.074
201809 -0.084 99.900 -0.093
201812 -0.030 99.700 -0.033
201903 0.086 99.700 0.095
201906 0.088 99.800 0.098
201909 0.164 100.100 0.181
201912 0.169 100.500 0.186
202003 0.056 100.300 0.062
202006 -0.031 99.900 -0.034
202009 0.114 99.900 0.126
202012 0.274 99.300 0.305
202103 0.122 99.900 0.135
202106 0.066 99.500 0.073
202109 0.194 100.100 0.215
202112 0.216 100.100 0.239
202203 0.260 101.100 0.285
202206 -0.225 101.800 -0.245
202209 0.080 103.100 0.086
202212 0.173 104.100 0.184
202303 0.132 104.400 0.140
202306 -0.383 105.200 -0.403
202309 0.150 106.200 0.156
202312 -0.105 106.800 -0.109
202403 0.207 107.200 0.214
202406 0.057 108.200 0.058
202409 0.320 108.900 0.325
202412 0.106 110.700 0.106

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Olympus  (OTCPK:OCPNF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Olympus Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Olympus's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Olympus Business Description

Traded in Other Exchanges
Address
Shinjuku Monolith, 2-3-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, JPN, 163-0914
Olympus is a medical device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2025, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.